Management of Nausea in Gastric Sleeve Patients

First-Line Treatment

• The National Comprehensive Cancer Network recommends prochlorperazine as a first-line breakthrough antiemetic when adding an agent from a different drug class, with a dosing regimen of 10 mg PO/IV every 4-6 hours 1
• Prochlorperazine works as a dopamine antagonist through a different pathway than metoclopramide, making it effective even when metoclopramide has failed 2, 3

Second-Line Treatment

• Olanzapine 2.5-5 mg PO BID is recommended as a second-line option if prochlorperazine is insufficient, with advantages including high efficacy for refractory nausea and a different mechanism of action 1
• The American College of Clinical Pharmacology suggests that olanzapine can be used with caution in patients with diabetes, such as those on Mounjaro, with close monitoring of glucose levels 1

Adjunctive Therapies

• Dexamethasone 8-12 mg PO/IV daily can be added to any of the above regimens for enhanced efficacy, working through anti-inflammatory mechanisms with minimal anticholinergic properties 3, 1, 4
• Lorazepam 0.5-2 mg PO/IV/SL every 4-6 hours can be added for anxiety-related nausea or anticipatory nausea, especially useful if the patient has anxiety about eating or taking medications due to nausea history 3, 1, 4, 5

Critical Management Principles

• The National Comprehensive Cancer Network suggests switching to scheduled dosing rather than PRN once breakthrough nausea occurs to maintain therapeutic levels 1
• The general principle is to add an agent from a different drug class rather than replacing failed therapy, with multiple concurrent agents from different classes may be necessary for adequate control 3, 1, 2